APIs

Eltrombopag olamine

Eltrombopag, also known as SB-497115-GR, is an agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was initially approved by in 2008, for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy. In preclinical studies, Eltrombopag was shown to interact selectively with the thrombopoietin receptor, leading to activation of the JAK-STAT signaling pathway and increased proliferation and differentiation of megakaryocytes....
Products Inquiry

Description

Product Name:   Eltrombopag olamine
Synonyms:   Promacta; Revolade; SB 497115GR; Unii-4U07F515lg 3'-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazinyl]-2'- hydroxy-[1,1'-biphenyl]-3-carboxylic acid compd. with 2-aminoethanol
Description:   Red to brown powder
Cas No.:   496775-62-3
Molecular Formula:   C25H22N4O4.2(C2H7NO)
Molecular Weight:   564.64
Purity:   99%min HPLC
Quality Standard:   Enterprise standard
Usage:   1.  Eltrombopag olamine is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
2.  Eltrombopag olamine is indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.
3.  Eltrombopag olamine is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.